Llwytho...
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Acta Biochim Biophys Sin (Shanghai) |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/ https://ncbi.nlm.nih.gov/pubmed/26578706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|